BRLS vs JVA

The company exhibits severe financial distress with a Piotroski F-Score of just 1/9, indicating very weak fundamental health. Profitability metrics are deeply negative, with a -65.72% profit margin and -13.56% ROA, while liquidity is critically impaired (Current Ratio: 0.15, Quick Ratio: 0.04). Revenue is declining YoY (-7.60%), and the stock has lost over 90% of its value in the past three years. Despite a low Price/Sales ratio of 0.75, the absence of reliable earnings, cash flow, and balance sheet data, combined with no Graham or Altman scores, suggests extreme risk.

JVA presents a classic deep-value paradox: it is significantly undervalued relative to its Graham Number ($6.21) and Intrinsic Value ($10.03), yet it suffers from a bearish technical trend (0/100) and weak insider sentiment. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, though the balance sheet is exceptionally clean with a low Debt/Equity ratio of 0.17 and a strong Current Ratio of 3.06. While YoY growth metrics are impressive, the company's razor-thin profit margins (1.89%) and erratic earnings track record create significant operational risk. The stock is a value play that lacks a catalyst for price appreciation.